LongTECHJun 2026
Bio-Techne Corp.
Merck KGaA agreed to acquire Bio-Techne for $73.00 per share in cash. The transaction values the life-sciences tools and diagnostics company at approximately $11 billion. The…
TECH
Which hedge funds are long TECH?
1 published idea on Bio-Techne Corp. across 1 fund — 1 long and 0 short.
Bio-Techne hedge fund investment theses
Each stock pitch below comes from a fund manager's own investor letter, not a 13F filing, so it carries the reasoning behind the portfolio position on Bio-Techne: the full investment thesis, the risks the manager flagged, the conviction level and the time horizon. Positions may have changed since the letter was written.